StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) company profile

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

About Keros Therapeutics

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biopharmaceutical organization focused on discovering, developing, and commercializing novel protein therapeutics for disorders linked to dysfunctional transforming growth factor-beta (TGF-ß) signaling pathways. Its pipeline centers on engineered ligand traps designed to target tissues such as skeletal muscle, bone, adipose tissue, and blood. The primary product candidate, rinvatercept, targets neuromuscular conditions including Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its other key candidate, elritercept, addresses cytopenias such as anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. The company aims to serve patient populations suffering from rare neuromuscular and hematological disorders.

Operating as a development-stage biopharmaceutical enterprise, the company conducts preclinical studies and clinical trials, including global collaborative partnerships. It has established an exclusive licensing agreement covering the worldwide development, manufacturing, and commercialization of elritercept outside of mainland China, Hong Kong, and Macau. The provided excerpt does not disclose the company's specific headquarters location or physical facility count.

Summary of the business section of Keros Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Keros Therapeutics, Inc.
Headquarters
Lexington, MA
Address
1050 Waltham Street, Suite 302 02421
Phone
(617) 314-6297
Employees
78, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Boston, MA

Stock & identifiers

Ticker
KROS
Exchange
Nasdaq
IPO date
Apr 8, 2020
Shares outstanding
20M, Jul 27, 2026
Public float
$453.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1664710
CUSIP
492327101
ISIN
US4923271013
FIGI
BBG00H1HP9G9
Share class FIGI
BBG00H1HP9H8
EIN
81-1173868

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jasbir SeehraCHIEF EXECUTIVE OFFICER, Director440,708
Lorena Raquel LernerChief Scientific Officer27,559
Annita TaniniCorp. Controller & VP, Finance45,144
Esther ChoChief Legal Officer35,770
Keith RegnanteCHIEF FINANCIAL OFFICER39,261
Yung H. ChyungChief Medical Officer44,000
Christopher RovaldiChief Operating Officer60,000
Anne PrenerDirector13,212
Charles W. NewtonDirector12,114
Jean Jacques BienaimeDirector19,592
Nima FarzanDirector9,767
Julius KnowlesDirector161,005
Mary Ann GrayDirector12,392
Alpna SethDirector12,392
Carl L. GordonDirector764,405
Genesis GP LLC OrbiMedDirector45,057
Capital GP VII LLC OrbiMedDirector148,922
Advisors Llc OrbimedDirector–
Ran NussbaumDirector160,512
Tomer KarivDirector160,512

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.54M$3.71M$1.23M$29–
FY2024$6.27M$2.70M$4.17M$22–
FY2023$8.93M$3.44M$3.04M$56–
FY2022$6.46M$710.05K$3.28M$68$90
FY2021$7.23M-$4.45M$2.88M$83$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Jasbir Seehra
President and Chief Executive Officer
$700.00K$1.43M$398.13K$15.80K$2.54M-60%
Keith Regnante
Chief Financial Officer
$470.38K$464.64K$164.85K$14.00K$1.11M-51%
Esther Cho
Chief Legal Officer
$459.19K$464.64K$161.00K$14.00K$1.10M–
Christopher Rovaldi
Former President and Chief Operating Officer
$578.92K$871.20K–$25.99K$1.48M-79%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 8, 2020
Offer price
$16.00
Securities offered
6,000,000
Gross proceeds
$96.00M
Exchange
Nasdaq
First trading day
Apr 8, 2020
First-day close
$20.08+25.5%
Lock-up ends (est.)
Oct 5, 2020

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 78 full-time employees, including 27 who hold Ph.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?